サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1645704

安定同位体標識化合物の世界市場：タイプ別、用途別、エンドユーザー別 - 機会分析と産業予測、2024年～2035年

Stable Isotope Labeled Compounds Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

出版日
ページ情報
英文 317 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
安定同位体標識化合物の世界市場：タイプ別、用途別、エンドユーザー別 - 機会分析と産業予測、2024年～2035年
出版日: 2024年11月01日
発行: Allied Market Research
ページ情報: 英文 317 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

安定同位体標識化合物市場は、2023年には2億9,182万米ドルとなり、2024年から2035年までのCAGRは3.1％を示し、2035年までには4億2,010万米ドルに達すると予測されています。

安定同位体標識化合物は、1つ以上の原子が炭素13（^13C）、窒素15（^15N）、重水素（^2H）などの非放射性同位体で置き換えられた分子です。これらの同位体は、化学的には天然に存在するものと同じですが、原子質量が異なるため、放射線を出さずに追跡することができます。研究および産業用途で広く使用されており、代謝経路、医薬品開発、環境プロセスの研究において重要な役割を果たしています。非放射性であるため、生物学的分析にも化学的分析にも安全に使用でき、分子の挙動、反応機構、相互作用について詳細なレベルでの貴重な知見を得ることができます。

安定同位体標識化合物市場の成長は、様々な分野での有用性を高める様々な相互関連要因に大きく影響されています。質量分析や核磁気共鳴（NMR）などの高度な分析技術に対する需要の高まりは、極めて重要な役割を果たしています。これらの技術は、正確な測定と高分解能分析を達成するために安定同位体標識化合物に大きく依存しており、そのため採用が促進されています。研究や診断用途が高度化するにつれて、正確で信頼性の高い分析ツールの必要性が高まり、市場の成長をさらに後押ししています。さらに、環境研究における安定同位体標識化合物の用途の増加は、その汎用性を浮き彫りにしています。これらの化合物は汚染物質の追跡や環境変化のモニタリングに使用され、規制や環境保全の取り組みに不可欠なデータを提供します。このような応用により、世界の環境課題への対応における安定同位体標識化合物の重要性が高まり、市場の成長が促進されます。

Stable Isotope Labeled Compounds Market-IMG1

臨床試験とプロテオミクス研究の拡大は、もう一つの重要な推進力となっています。安定同位体標識化合物は、薬物代謝や生体システム内の複雑な相互作用を理解するために不可欠です。臨床試験では新薬の代謝経路を追跡するのに役立ち、プロテオミクスではタンパク質の正確な定量と追跡が可能になります。臨床とプロテオミクスのアプリケーションにおけるこの成長は、医学研究と個別化医療を前進させるために、これらの化合物への依存が高まっていることを反映しています。

さらに、研究者や臨床医の間で安定同位体標識化合物に対する認識と採用が高まっていることも、市場成長を促進する主な要因となっています。研究者や臨床医が、様々な研究の正確性や信頼性を高める能力など、安定同位体標識化合物に関連する利点に精通するにつれて、これらの化合物の使用量が増加しています。このような安定同位体標識化合物の価値に対する認識の高まりは、多様な科学・臨床分野での需要の増加にさらに貢献し、市場全体の成長を促進する相乗効果を生み出しています。

安定同位体標識化合物市場は、タイプ、用途、エンドユーザー、地域に区分されます。タイプ別では、市場は重水素、炭素-13、酸素-18、窒素-15、その他に区分されます。用途別では、市場は研究、臨床診断、その他に分類されます。研究セグメントはさらに生物医学研究、製薬研究、その他に分けられます。エンドユーザー別では、製薬・バイオテクノロジー企業、学術・研究機関、病院・診断センター、その他のエンドユーザーに分類されます。地域別では、市場は北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカで分析されます。

利害関係者にとっての主なメリット

  • 当レポートでは、2023年から2035年までの安定同位体標識化合物市場分析の市場セグメント、現在の動向、推定・動向、ダイナミクスを定量的に分析し、有力な安定同位体標識化合物市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • 安定同位体標識化合物市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場企業のポジショニングはベンチマーキングを容易にし、市場企業の現在のポジションを明確に理解することができます。
  • 地域別および世界の安定同位体標識化合物市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を含みます。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主要な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • がん罹患率の上昇と調査の進歩
      • 政府の資金援助と支援の拡大
      • 主要企業による戦略採用の増加
    • 抑制要因
      • 製造コストの高さと技術的複雑性
    • 機会
      • 新興国における成長機会

第4章 安定同位体標識化合物市場：タイプ別

  • 概要
  • 重水素
  • 炭素13
  • 酸素18
  • 窒素15
  • その他

第5章 安定同位体標識化合物市場：用途別

  • 概要
  • 研究
    • 研究用の安定同位体標識化合物市場：タイプ別
  • 臨床診断
  • その他

第6章 安定同位体標識化合物市場：エンドユーザー別

  • 概要
  • 製薬企業・バイオテクノロジー企業
  • 学術・研究機関
  • 病院・診断センター
  • その他

第7章 安定同位体標識化合物市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • その他
  • ラテンアメリカ、中東・アフリカ
    • ブラジル
    • 南アフリカ
    • サウジアラビア
    • その他

第8章 競争情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第9章 企業プロファイル

  • Merck KGaA
  • Otsuka Holdings Co., Ltd.
  • Entegris
  • Omicron Biochemicals, Inc.
  • Shimadzu Corporation
  • Silantes
  • VIVAN Life Sciences
  • BOC Sciences
  • Symeres
  • NIPPON SANSO HOLDINGS CORPORATION
目次
Product Code: A07585

The stable isotope labeled compounds market was valued at $291.82 million in 2023 and is estimated to reach $420.1 million by 2035, exhibiting a CAGR of 3.1% from 2024 to 2035. Stable isotope-labeled compounds are molecules where one or more atoms are replaced with non-radioactive isotopes, such as carbon-13 (^13C), nitrogen-15 (^15N), deuterium (^2H), and others. These isotopes are chemically identical to their naturally occurring counterparts but differ in atomic mass, allowing them to be tracked without emitting radiation. Widely used in research and industrial applications, they play a crucial role in studying metabolic pathways, drug development, and environmental processes. Their non-radioactive nature makes them safe for use in both biological and chemical analyses, providing valuable insights into molecular behavior, reaction mechanisms, and interactions at a detailed level.

The growth of the stable isotope-labeled compounds market is significantly influenced by a range of interconnected factors that enhance its utility across various fields. The rise in demand for advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) plays a pivotal role. These techniques rely majorly on stable isotope-labeled compounds to achieve precise measurements and high-resolution analysis, thus driving their adoption. The need for accurate and reliable analytical tools increases, as research and diagnostic applications become sophisticated, further fueling market growth. In addition, the increase in application of stable isotope-labeled compounds in environmental studies highlights their versatility. These compounds are used to trace pollutants and monitor environmental changes, providing crucial data for regulatory and conservation efforts. This application drives the growing importance of stable isotope-labeled compounds in addressing global environmental challenges, thus fostering the market growth.

Stable Isotope Labeled Compounds Market - IMG1

The expansion of clinical trials and proteomics studies represents another crucial driver. Stable isotope-labeled compounds are essential for understanding drug metabolism and the complex interactions within biological systems. In clinical trials, they help in tracing the metabolic pathways of new drugs, while in proteomics, they enable precise protein quantification and tracking. This growth in clinical and proteomics applications reflects the increasing reliance on these compounds for advancing medical research and personalized medicine.

Moreover, the rise in awareness and adoption of stable isotope-labeled compounds among researchers and clinicians is a key factor driving the market growth. There is an increase in the usage of these compounds as researchers and clinicians become familiar with the benefits associated with them, including their ability to enhance accuracy and reliability in various studies. This growing recognition of the value of stable isotope-labeled compounds further contributes to their increasing demand across diverse scientific and clinical fields, creating a synergistic effect that drives the overall market growth.

The stable isotope-labeled compounds market is segmented into type, application, end user, and region. On the basis of type, the market is segmented into Deuterium, Carbon-13, Oxygen-18, Nitrogen-15, and others. On the basis of application, the market is classified into research, clinical diagnostics, and other. The research segment is further divided into biomedical research, pharma research, and others. On the basis of end user, the market is categorized into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, and other end users. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Merck KGaA, Otsuka Holdings Co., Ltd., Entegris, Omicron Biochemicals, Inc., Shimadzu Corporation, Nippon Sanso Holding Corporation, Vivan Life Sciences, BOC Sciences, Silantes, and Symeres. The key players have adopted product launch, geographical expansion, partnership, and agreement as the key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stable isotope labeled compounds market analysis from 2023 to 2035 to identify the prevailing stable isotope labeled compounds market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the stable isotope labeled compounds market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global stable isotope labeled compounds market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Deuterium
  • Carbon 13
  • Oxygen 18
  • Nitrogen15
  • Other

By Application

  • Research
    • Type
    • Biomedical Research
    • Pharma Research
    • Others
  • Clinical Diagnostics
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospitals and Diagnostic Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa,
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • BOC Sciences
    • Entegris
    • Merck KGaA
    • NIPPON SANSO HOLDINGS CORPORATION
    • Omicron Biochemicals, Inc.
    • Otsuka Holdings Co., Ltd.
    • Shimadzu Corporation
    • Silantes
    • Symeres
    • VIVAN Life Sciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in Cancer Prevalence and Advancements in Research
      • 3.4.1.2. Growing Government Funding and Support
      • 3.4.1.3. Rise in adoption of strategies by the key players
    • 3.4.2. Restraints
      • 3.4.2.1. High Production Costs and Technical Complexity
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth Opportunity in emerging countries

CHAPTER 4: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Deuterium
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Carbon 13
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Oxygen 18
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Nitrogen15
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Research
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Research Stable Isotope Labeled Compounds Market by Type
  • 5.3. Clinical Diagnostics
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Academic and Research Institutes
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Hospitals and Diagnostic Centers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. Rest of Asia-Pacific
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. South Africa,
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Saudi Arabia
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Merck KGaA
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Otsuka Holdings Co., Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Entegris
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Omicron Biochemicals, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Shimadzu Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Silantes
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. VIVAN Life Sciences
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. BOC Sciences
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Symeres
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. NIPPON SANSO HOLDINGS CORPORATION
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance